Long acting GLP-1 receptor agonist (injectable)
Efpeglenatide 16 mg injection every 4 weeks
EFPE_SC_16MG_Q4W
Related
- All doses pooled: Efpe sc
- Efpe sc 1mg qw
- Efpeglenatide 2 mg subcutaneous once weekly
- Efpeglenatide 4 mg subcutaneous once weekly
- Efpe sc 8mg qm
- Efpe sc 12mg qm
- Efpeglenatide 16 mg injection monthly
- Efpeglenatide 8 mg injection every 4 weeks
- Efpeglenatide 12 mg injection every 4 weeks
- Efpeglenatide 6 mg subcutaneous once weekly
- Efpeglenatide 6 mg injection every 2 weeks
- Efpeglenatide 8 mg injection every 2 weeks
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.62 (0.01 to 40.38) | 0.67 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 1.52 (0.27 to 9.04) | 0.35 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 4.92 (1.13 to 27.47) | 0.20 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 13.72 (4.04 to 62.00) | 0.07 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 7.07 (2.16 to 29.86) | 0.22 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 2.60 (0.90 to 8.54) | 0.30 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.86 (0.05 to 13.31) | 0.47 |